Table S3. Clinically relevant nosocomial infections that occurred within our study population during their ICU admission.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Patient ID** | **Infection** | **Culture results** | **Antibiotic regimen** | **Duration** |
| 1 | Pneumonia | BAL – *E. coli*, *Serratia liquifaciens*, alpha hemolytic streptococcus | Piperacillin-tazobactam + vancomycin 🡪 cefepime 🡪 cefuroxime | 8 days |
| 3 | Pneumonia | BAL – *E.coli*, *S. aureus*, alpha hemolytic streptococcus, non-cryptococcus yeast | Cefepime + metronidazole + vancomycin | 8 days |
| 12 | Pneumonia | BAL – *Stenotrophomonas maltophilia* | Cefepime + metronidazole + vancomycin 🡪 levofloxacin | 8 days |
| 17 | Pneumonia | BAL – beta hemolytic group C streptococcus, diphtheroids | Cefepime + vancomycin | 10 days |
| 17 | Bacteremia | Blood – *S. epidermidis* | Vancomycin | 17 days |
| 18 | Pneumonia | BAL – unidentified Gram negative rods | Cefepime + vancomycin 🡪 cefepime + metronidazole + vancomycin | 8 days |
| 21 | Pneumonia | BAL – alpha hemolytic streptococcus | Cefepime + vancomycin | 5 days |
| 23 | Pneumonia | BAL – *Citrobacter koseri*, *Enterobacter cloaecae*, *Haemophilus influenzae*, *Stenotrophomonas maltophila*BAL – *Stenotrophomonas maltophilia* | Cefepime + vancomycin 🡪 levofloxacin | 17 days |
| 31 | Pneumonia | BAL - *Enterobacter cloaecae*, *Pseudomonas aeruginosa*, *S. aureus*, alpha hemolytic strep, non-hemolytic strep | Piperacillin-tazobactam | 8 days |
| 31 | Pneumonia | BAL - *Enterobacter cloacae*, *Pseudomonas aeruginosa* | Cefepime | 8 days |